Gartel Andrei L
Department of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612 USA,
Cancer Biol Ther. 2007 Aug;6(8):1171-2. doi: 10.4161/cbt.6.8.4712. Epub 2007 Jul 9.
The cyclin-dependent kinase inhibitor p21WAF1/CIP1 was originally considered to be a tumor-suppressor because it was identified as a key mediator of p53-dependent cell cycle arrest. However, it has been suggested that p21 may also act as an oncogene because it often inhibits apoptosis. For example, deletion of p21 from p53-deficient mice resulted in longer survival and in a significantly reduced number of thymic lymphomas that was explained by higher apoptotic rates in these mice. However, recently it has been shown that a p53 mutant that had lost its ability to induce apoptosis, but retained its ability to induce p21 and cell cycle arrest, was able to suppress lymphomagenesis in different cancer models. Tumor suppression by this p53 mutant was modulated by p21, which induced senescence and preserved chromosomal stability. These data suggest that the ability of p21 to induce cell-cycle arrest may lead to tumor suppression in some types of cancer.
细胞周期蛋白依赖性激酶抑制剂p21WAF1/CIP1最初被认为是一种肿瘤抑制因子,因为它被确定为p53依赖性细胞周期阻滞的关键介质。然而,有人提出p21也可能作为一种癌基因起作用,因为它常常抑制细胞凋亡。例如,从p53缺陷小鼠中删除p21会导致更长的生存期,并且胸腺淋巴瘤的数量显著减少,这可以通过这些小鼠较高的凋亡率来解释。然而,最近有研究表明,一种失去诱导细胞凋亡能力但保留诱导p21和细胞周期阻滞能力的p53突变体,能够在不同的癌症模型中抑制淋巴瘤的发生。这种p53突变体的肿瘤抑制作用受到p21的调节,p21诱导细胞衰老并维持染色体稳定性。这些数据表明,p21诱导细胞周期阻滞的能力可能在某些类型的癌症中导致肿瘤抑制。